Skip to main content

Table 3 Impact of role-playing on mastery of key concepts in genetic counseling (N = 200)

From: Role-playing is an effective instructional strategy for genetic counseling training: an investigation and comparative study

No.

Key concepts of genetic counseling

Average rank in

Change

(95 % CI)

Paired t test

P value

Pre-test

Post-test

1

Congenital disease

2.05 ± 0.605

2.90 ± 0.308

-0.85

(-1.12 -0.58)

<0.0001

2

Familial disease

2.10 ± 0.6411

2.95 ± 0.224

-0.85

(-1.12 -0.58)

< 0.0001

3

Genetic disease

2.15 ± 0.587

3.00 ± 0.000

-0.85

(-1.12 -0.58)

< 0.0001

4

Genetic maker

0.30 ± 0.470

2.85 ± 0.366

-2.55

(-2.83 -2.27)

< 0.0001

5

Epigenetic

0.70 ± 0.979

2.85 ± 0.366

-2.15

(-2.68 -1.62)

< 0.0001

6

Mitosis

2.85 ± 0.366

3.00 ± 0.000

-0.15

(-0.32 0.02)

0.0828 (NS)

7

Meiosis

2.85 ± 0.366

3.00 ± 0.000

-0.15

(-0.32 0.02)

0.0828 (NS)

8

Dynamic mutation

0.50 ± 0.827

2.75 ± 0.444

-2.25

(-2.62 -1.88)

< 0.0001

9

Euchromatin

2.25 ± 0.910

2.95 ± 0.224

-0.70

(-1.13 -0.27)

0.0031

10

Heterochromatin

1.85 ± 0.933

2.85 ± 0.366

-1.00

(-1.48 -0.52)

0.0003

11

Sex chromatin

2.35 ± 0.875

2.95 ± 0.224

-0.60

(-0.95 -0.25)

0.0021

12

Karyotype

0.40 ± 0.503

2.85 ± 0.366

-2.45

(-2.73 -2.17)

< 0.0001

13

Pedigree

0.50 ± 0.688

2.95 ± 0.224

-2.45

(-2.77 -2.13)

< 0.0001

14

Trisomy 21 syndrome

2.10 ± 0.718

3.00 ± 0.000

-0.90

(-1.24 -0.56)

< 0.0001

15

Trisomy 18 syndrome

0.30 ± 0.571

2.65 ± 0.489

-2.35

(-2.73 -1.97)

< 0.0001

16

Trisomy 13 syndrome

0.25 ± 0.444

2.60 ± 0.503

-2.35

(-2.66 -2.04)

< 0.0001

17

Turner syndrome

0.80 ± 0.894

2.95 ± 0.224

-2.15

(-2.56 -1.74)

< 0.0001

18

Klinefelter syndrome

0.05 ± 0.224

2.75 ± 0.444

-2.70

(-2.97 -2.43)

< 0.0001

19

Huntington chorea

1.65 ± 0.875

2.60 ± 0.754

-0.95

(-1.53 -0.37)

0.0027

20

Albinism type I

2.00 ± 0.562

2.75 ± 0.444

-0.75

(-1.05 -0.45)

< 0.0001

21

Vitamin D resistant rickets

1.95 ± 0.605

2.55 ± 0.510

-0.60

(-0.98 -0.22)

0.0040

22

Duchenne muscular dystrophy

0.80 ± 0.696

2.20 ± 0.696

-1.40

(-1.75 -1.05)

< 0.0001

23

Heterogeneity

0.25 ± 0.444

2.90 ± 0.308

-2.65

(-2.88 -2.42)

< 0.0001

24

Genetic anticipation

0.15 ± 0.366

2.90 ± 0.308

-2.75

(-2.96 -2.54)

< 0.0001

25

Genetic imprinting

0.15 ± 0.366

2.85 ± 0.366

-2.70

(-2.97 -2.43)

< 0.0001

26

Delayed dominance

0.05 ± 0.224

3.00 ± 0.000

-2.95

(-3.05 -2.85)

< 0.0001

27

Irregular dominance

0.05 ± 0.224

2.90 ± 0.308

-2.85

(-3.02 -2.68)

< 0.0001

28

Incomplete dominance

0.75 ± 0.639

2.95 ± 0.224

-2.20

(-2.53 -1.87)

< 0.0001

29

Gene pleiotropy

0.50 ± 0.688

2.80 ± 0.523

-2.30

(-2.64 -1.96)

< 0.0001

30

Quantitative trait

0.05 ± 0.224

3.00 ± 0.000

-2.95

(-3.05 -2.85)

< 0.0001

31

Qualitative trait

0.05 ± 0.224

3.00 ± 0.000

-2.95

(-3.05 -2.85)

< 0.0001

32

Genetic susceptibility

0.20 ± 0.410

3.00 ± 0.000

-2.80

(-2.99 -2.61)

< 0.0001

33

Genetic liability

0.05 ± 0.224

3.00 ± 0.000

-2.95

(-3.05 -2.85)

< 0.0001

34

Coefficient of relationship

0.35 ± 0.489

3.00 ± 0.000

-2.65

(-2.88 -2.42)

< 0.0001

35

Inbreeding coefficient

0.35 ± 0.489

2.95 ± 0.224

-2.60

(-2.84 -2.36)

< 0.0001

36

Law of genetic equilibrium

0.40 ± 0.598

3.00 ± 0.000

-2.60

(-2.88 -2.32)

< 0.0001

37

Mitochondrial disease

1.25 ± 0.851

2.60 ± 0.503

-1.35

(-1.73 -0.97)

< 0.0001

38

Genetic hypothesis of tumorigenesis

0.60 ± 0.598

2.85 ± 0.366

-2.25

(-2.55 -1.95)

< 0.0001

39

Gene therapy

1.15 ± 0.489

2.80 ± 0.410

-1.65

(-2.00 -1.30)

< 0.0001

40

Genetic diagnosis

1.25 ± 0.550

2.85 ± 0.366

-1.60

(-1.88 -1.32)

< 0.0001

41

Genetic counseling

1.00 ± 0.725

2.80 ± 0.410

-1.80

(-2.19 -1.41)

< 0.0001

42

Genetic screening

0.80 ± 0.768

2.55 ± 0.510

-1.75

(-2.20 -1.30)

< 0.0001

  1. NS Not Significant (P > 0.05)
Back to article page

BMC Medical Education

ISSN: 1472-6920

Contact us